key: cord-1048951-dpf394iu
authors: Janapal, Rajesh Naidu; Patel, Jigar; Belfaqeeh, Omar; Pourmand, Ali
title: Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
date: 2021-06-16
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2021.107878
sha: c59b1e814a8feb9f328af73d3779ac4443dc1e51
doc_id: 1048951
cord_uid: dpf394iu

We appreciate the efforts of the authors in their study on the clinical outcome of hydroxychloroquine (HCQ) therapy in mild coronavirus disease 2019 (COVID-19) (Mokhtari et al., 2021). We would like to make some comments based on our understanding of the study.

Patients with mild COVID-19 and who did not require hospitalization received HCQ therapy. COVID -19 was diagnosed in patients who presented with clinical symptoms and either a reverse transcriptasepolymerase chain reaction (RT-PCR) or chest imaging. In table 1, it is reported that 470 patients with a negative PCR test received HCQ and 861 patients with no test received HCQ. We would like to know why those patients with a negative RT-PCR test received HCQ therapy. We are assuming that the no test patients' group must be those that were diagnosed with imaging.

In table 1, it is also reported that the rates of hospitalization in patients with a negative PCR test were 5.11% in those who received HCQ and 10.86% in those who did not receive HCQ. Similarly, the percentage of death in patients with a negative PCR test was 0.21 in those who received HCQ and 0.28 in those who did not receive HCQ. It is very interesting to see that rates of hospitalizations and deaths were low in patients who received HCQ compared to those who did not receive HCQ despite their COVID-19 test being negative. It suggests that one's risk of hospitalization and death is reduced by taking HCQ irrespective of their COVID-19 diagnosis. We are interested to know the rationale behind this outcome.

The reported outcomes of the study were COVID-19 related hospitalizations or mortality during sixmonths follow-up. As COVID-19 is an acute disease process, it is interesting to know what led the authors to choose to do such a long follow-up for mortality rates.

Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting

Keywords: Mild COVID-19, Hydroxychloroquine, HCQ, Hospitalization, Mortality Declarations of interest: none

The authors stated that the patients were followed daily for 5 days and on day 14 for the outcomes, adverse reactions to HCQ, and disease progression after the initiation of HCQ therapy. However, the time to symptoms resolution was not reported. We believe that reporting the time to symptom resolution would have been helpful to know if therapy with HCQ reduces the time to symptom resolution.The authors reported a lack of access to other medication received by the patients as one of the limitations of their study. Though the authors have acknowledged it, we believe that the data on other medications received is very important. Not having the data on other medications received may have potentially introduced a confounding into this study's results.

All the authors were part of the critical appraisal of the study.Rajesh Naidu Janapala drafted the manuscript.Ali Pourmand reviewed and edited.All the authors revised the manuscript critically before submission.

 The study did not report any exclusion criteria.  Why the patients with a negative RT-PCR test received Hydroxychloroquine therapy?  Hospitalization and mortality benefits with HCQ even when RT-PCR is negative?